Peter Goodfellow
InvestorSenior Advisor at Abingworth
About
Peter Goodfellow previously served as Senior Vice President for Discovery Research at GlaxoSmithKline and held the Balfour chair in genetics at Cambridge University, along with research positions at the Imperial Cancer Research Fund. He chaired the boards of GammaDelta Therapeutics and Adaptate Biotherapeutics, both Abingworth portfolio companies. He holds doctorates from Oxford and Bristol Universities and is a Fellow of EMBO, the Academy of Medical Sciences, and the Royal Society.
Invests in
Biotech
Investments
Board seats
Adaptate BiotherapeuticsGammaDelta Therapeutics
Per the firm's website.
Colleagues at Abingworth
Alex Asquith
Counsel at Abingworth
Andrew Sinclair
Managing Director, Head of Publics & Late Stage at Abingworth
Ankur Shah
Vice President, CCD at Abingworth
Anna Slezak
Senior Associate at Abingworth
Bali Muralidhar
Global Head of Life Sciences & CIO at Abingworth
Carlos Paya
Venture Partner at Abingworth
Dayle Hogg
Operating Executive at Abingworth
Diya Malhotra
Principal at Abingworth